Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (25)

2022

  1. Molecular diagnosis in non-small-cell lung cancer: Expert opinion on ALK and ROS1 testing

    Journal of Clinical Pathology, Vol. 75, Núm. 3, pp. 145-153

2019

  1. Generation of an induced pluripotent stem cell line (CIMAi001-A) from a compound heterozygous Primary Hyperoxaluria Type I (PH1) patient carrying p.G170R and p.R122* mutations in the AGXT gene.

    Stem Cell Research, Vol. 41

2016

  1. Transient expression of transgenic IL-12 in mouse liver triggers unremitting inflammation mimicking human autoimmune hepatitis

    Journal of Immunology, Vol. 197, Núm. 6, pp. 2145-2156

2009

  1. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders

    The Lancet Neurology, Vol. 8, Núm. 12, pp. 1140-1149

2008

  1. Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease

    Movement Disorders, Vol. 23, Núm. SUPPL. 3

  2. Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys

    Movement Disorders, Vol. 23, Núm. 5, pp. 708-715

  3. Neuronal activity of the red nucleus in Parkinson's disease

    Movement Disorders, Vol. 23, Núm. 6, pp. 908-911

  4. The basal ganglia in Parkinson's disease: Current concepts and unexplained observations

    Annals of Neurology, Vol. 64, Núm. SUPPL. 2

2007

  1. Bone-marrow-derived cell differentiation into microglia: A study in a progressive mouse model of Parkinson's disease

    Neurobiology of Disease, Vol. 28, Núm. 3, pp. 316-325

2006

  1. Glycine release in the substantia nigra: Interaction with glutamate and GABA

    Neuropharmacology, Vol. 50, Núm. 5, pp. 548-557

2005

  1. Optimization of use of levodopa in Parkinson's disease: Role of levodopa-carbidopa-entacapone combination

    Neurologia, Vol. 20, Núm. 4, pp. 180-188

2004

  1. How does Parkinson's disease begin? The role of compensatory mechanisms (multiple letters)

    Trends in Neurosciences

  2. The origin of motor fluctuations in Parkinson's disease: Importance of dopaminergic innervation and basal ganglia circuits

    Neurology, Vol. 62, Núm. 1 SUPPL. 1

2003

  1. Firing regulation in dopaminergic cells: Effect of the partial degeneration of nigrostriatal system in surviving neurons

    European Journal of Neuroscience, Vol. 18, Núm. 1, pp. 53-60

  2. How is firing activity of substantia nigra cells regulated? Relevance of pattern-code in the basal ganglia

    Synapse, Vol. 49, Núm. 4, pp. 216-225

  3. Neuronal activity in the substantia nigra in the anaesthetized rat has fractal characteristics. Evidence for firing-code patterns in the basal ganglia

    Experimental Brain Research, Vol. 151, Núm. 2, pp. 167-172

2002

  1. The basal ganglia and disorders of movement: Pathophysiological mechanisms

    News in Physiological Sciences, Vol. 17, Núm. 2, pp. 51-55

2001

  1. Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: An animal model of Parkinson's disease

    Behavioural Brain Research, Vol. 122, Núm. 1, pp. 79-92

  2. The subthalamic nucleus in Parkinson's disease: Somatotopic organization and physiological characteristics

    Brain, Vol. 124, Núm. 9, pp. 1777-1790

2000

  1. Pathophysiologic basis of surgery for Parkinson's disease

    Neurology, Vol. 55, Núm. 12 SUPPL. 6